On the road to common solutions in cell and gene therapy
The emerging field of cell and gene therapy (CGT) has only recently started being commercialized and so standard methods for generating therapeutic products continue to change. Companies are developing their own procedur...
The essential digital capabilities for CGT manufacturing to succeed at scale
Cell and gene therapies (CGTs) is an emerging, high-growth area, but their manufacture is different from established sma...
BioPhorum celebrates its 200th membership
Founded in 2008 with one Phorum, Drug Substance, the BioPhorum collaboration has focused on bringing leaders and SMEs to...
How industry is using technology during the COVID-19 pandemic
The use of technology in its many forms was a recurring theme in BioPhorum’s recent COVID-19 Workforce Protection Surv...
How to assess EHS risks for commercial-scale CGT manufacture
The rapidly expanding field of cell and gene therapies (CGT) has the potential to revolutionize curative treatments. How...
How is industry responding to the covid-19 pandemic?
During the covid-19 pandemic, it is even more important that we connect, share information and help each other meet the ...
Interested in being a BioPhorum peer reviewer?
Excellence has always been at the heart of everything we do – from holding face-to-face meetings to publishing technic...
How to learn about PUPSIT in terminal sterilizing filtration – the science, implications and implementation
How to learn about PUPSIT in terminal sterilizing filtration – the science, implications and implementation Pre-use po...
BioPhorum CGT – delivering and shaping industry approaches
Cell and gene therapies (CGT) are changing the treatment landscape for many diseases and, with each new headline, patien...
Mapping cell and gene therapy manufacturing
Cell and gene therapy (CGT) is a diverse field, with products and processes as varied as the patients it is trying to tr...
IT for Cell and Gene Therapy
In 2020 only a few cell and gene therapies (CGT) are approved for commercial use, but hundreds of clinical trials are un...
Current mission of the High-Level Analytics Workstream
The High-Level Analytics Workstream has been running since September 2018, with representatives from 21 member companies...
CGT Environmental Health and Safety (EHS) and BioSafety workstream
Running since September 2018, the EHS and BioSafety Workstream has representatives from 15 member companies. The 23 subj...
On the road to common solutions in cell and gene therapy
The emerging field of cell and gene therapy (CGT) has only recently started being commercialized and so standard methods...
The essential digital capabilities for CGT manufacturing to succeed at scale
Cell and gene therapies (CGTs) is an emerging, high-growth area, but their manufacture is different from established sma...
BioPhorum celebrates its 200th membership
Founded in 2008 with one Phorum, Drug Substance, the BioPhorum collaboration has focused on bringing leaders and SMEs to...
How industry is using technology during the COVID-19 pandemic
The use of technology in its many forms was a recurring theme in BioPhorum’s recent COVID-19 Workforce Protection Surv...
How to assess EHS risks for commercial-scale CGT manufacture
The rapidly expanding field of cell and gene therapies (CGT) has the potential to revolutionize curative treatments. How...
How is industry responding to the covid-19 pandemic?
During the covid-19 pandemic, it is even more important that we connect, share information and help each other meet the ...
Interested in being a BioPhorum peer reviewer?
Excellence has always been at the heart of everything we do – from holding face-to-face meetings to publishing technic...
How to learn about PUPSIT in terminal sterilizing filtration – the science, implications and implementation
How to learn about PUPSIT in terminal sterilizing filtration – the science, implications and implementation Pre-use po...
BioPhorum CGT – delivering and shaping industry approaches
Cell and gene therapies (CGT) are changing the treatment landscape for many diseases and, with each new headline, patien...
Mapping cell and gene therapy manufacturing
Cell and gene therapy (CGT) is a diverse field, with products and processes as varied as the patients it is trying to tr...
IT for Cell and Gene Therapy
In 2020 only a few cell and gene therapies (CGT) are approved for commercial use, but hundreds of clinical trials are un...
Current mission of the High-Level Analytics Workstream
The High-Level Analytics Workstream has been running since September 2018, with representatives from 21 member companies...
